List of Excipients in Branded Drug ONGLYZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	ONGLYZA	saxagliptin	0310-6105	CELLULOSE, MICROCRYSTALLINE
AstraZeneca Pharmaceuticals LP	ONGLYZA	saxagliptin	0310-6105	CROSCARMELLOSE SODIUM
AstraZeneca Pharmaceuticals LP	ONGLYZA	saxagliptin	0310-6105	LACTOSE MONOHYDRATE
AstraZeneca Pharmaceuticals LP	ONGLYZA	saxagliptin	0310-6105	MAGNESIUM STEARATE
Physicians Total Care Inc	ONGLYZA	saxagliptin	54868-6309	CELLULOSE, MICROCRYSTALLINE

Onglyza Excipient Strategy and Commercial Opportunities for Saxagliptin

Last updated: September 9, 2026

Onglyza is a small-molecule, immediate-release saxagliptin tablet marketed by AstraZeneca for type 2 diabetes. Its commercial formulation uses conventional, low-cost oral solid-dose excipients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a polyvinyl alcohol-based film coat. The principal opportunity is not a proprietary excipient platform. It is the supply, optimization, and differentiation of generic saxagliptin tablets and saxagliptin combination products after branded exclusivity constraints weaken.

What is Onglyza and how is it formulated?

Onglyza contains saxagliptin hydrochloride, a dipeptidyl peptidase-4 inhibitor. FDA approved Onglyza in 2009 for adults with type 2 diabetes as an adjunct to diet and exercise. The product is available as 2.5 mg and 5 mg immediate-release tablets administered once daily, with or without food (FDA, 2023).

The core formulation is a conventional compressed tablet.

Formulation element	Onglyza role	Commercial implication
Saxagliptin hydrochloride	Active pharmaceutical ingredient	Low-dose API; blend uniformity is important
Lactose monohydrate	Diluent and carrier	Cost-effective, established supply base; creates lactose-free positioning issues
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and direct compression
Croscarmellose sodium	Superdisintegrant	Enables rapid tablet breakup at low loading
Magnesium stearate	Lubricant	Excessive use may impair dissolution
Polyvinyl alcohol	Film-forming polymer	Standard coating system
Polyethylene glycol	Plasticizer in film coating	Reduces coating brittleness
Titanium dioxide and talc	Opacifying and anti-tacking agents	Conventional coating materials
Iron oxide pigments	Tablet color	Supports strength differentiation and identification

The inactive ingredients are listed in the FDA-approved product labeling rather than presented as a protected proprietary excipient system. The formulation therefore provides limited direct exclusivity for an excipient supplier. Its value is operational: reliable low-dose blending, tablet manufacturing, coating, stability, and regulatory support (FDA, 2023).

What excipients are used in Onglyza tablets?

The core Onglyza tablet uses four principal compression excipients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating contains polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, and colorants.

Why lactose and microcrystalline cellulose matter

Saxagliptin is present at a low dose relative to the tablet mass. Lactose and microcrystalline cellulose provide bulk and improve manufacturability. The combination is consistent with a direct-compression or dry-blending approach, although the exact manufacturing process and material grades are not necessarily disclosed in the public label.

For generic manufacturers, the critical controls are:

• API particle-size distribution
• Blend uniformity at low drug loading
• Excipient grade and moisture content
• Lubrication time
• Tablet hardness and friability
• Disintegration and dissolution
• Coating weight and color uniformity

A supplier able to provide narrow-variability lactose or microcrystalline cellulose, supported by strong change-control documentation, can compete for generic supply even without owning a formulation patent.

Why croscarmellose sodium is important

Croscarmellose sodium promotes rapid tablet disintegration by swelling and wicking water into the tablet matrix. Its performance depends on particle morphology, degree of substitution, moisture, and placement in the formulation.

Generic manufacturers can evaluate:

• Intra-granular versus extra-granular addition
• Alternative superdisintegrants
• Lower disintegrant loading
• Direct-compression grades
• Dissolution performance after scale-up

A formulation that matches the reference product's dissolution profile while reducing tablet weight or manufacturing cost may support a differentiated generic filing, subject to FDA requirements.

What does magnesium stearate contribute?

Magnesium stearate reduces adhesion to punches and dies. It can also slow wetting if over-lubrication occurs. For saxagliptin tablets, process control is more commercially relevant than excipient novelty.

Potential optimization areas include:

• Reduced lubrication time
• Alternative vegetable-derived or synthetic lubricants
• Improved powder-flow characteristics
• Lower ejection force
• Consistent dissolution across tablet presses

These changes normally create formulation know-how rather than strong standalone patent barriers.

What formulation opportunities exist for generic Onglyza?

The most practical opportunities are cost reduction, supply-chain resilience, patient-segment differentiation, and combination products.

Lactose-free saxagliptin tablets

The reference formulation contains lactose monohydrate. A generic manufacturer could replace lactose with anhydrous lactose, mannitol, dicalcium phosphate, spray-dried cellulose, or another suitable diluent.

A lactose-free product could target:

• Patients with lactose intolerance
• Hospital formularies seeking excipient restrictions
• Markets with lactose sourcing constraints
• Contract manufacturing programs requiring a broader excipient platform

The commercial benefit would depend on whether the alternative produces a meaningful clinical, procurement, or regulatory advantage. A lactose-free formulation alone is unlikely to command a large premium in a mature generic market.

Low-moisture and tropical-stability formulations

Excipient moisture can affect powder flow, tablet hardness, disintegration, and chemical stability. Manufacturers supplying humid or high-temperature markets may have an opportunity to develop:

• Low-moisture excipient systems
• High-barrier blister packaging
• Desiccant-supported bottle presentations
• Improved film coatings
• Stability-indicating manufacturing controls

The packaging system may create more practical value than a new excipient because immediate-release tablets are generally straightforward to formulate.

Smaller or easier-to-swallow tablets

Saxagliptin is a low-dose API, which creates room to optimize tablet dimensions. A smaller tablet could improve patient acceptability, particularly for older adults with polypharmacy.

Potential approaches include:

• Higher-density diluents
• More efficient superdisintegrants
• Reduced coating weight
• Optimized compression force
• Alternative tablet shapes

Any size reduction must preserve content uniformity, dissolution, mechanical strength, and bioequivalence.

Sprinkle or orally disintegrating formats

An orally disintegrating tablet, mini-tablet, or sprinkle formulation could address swallowing difficulty. These products would require additional development because taste, moisture sensitivity, mechanical robustness, and bioequivalence become more important.

The opportunity is technically feasible but commercially narrower than a standard generic tablet. It would be more attractive if supported by a specific adherence or geriatric-use strategy.

What combination-product opportunities exist for saxagliptin?

Saxagliptin has been commercialized in combination products, including saxagliptin/metformin extended-release under the Kombiglyze XR brand and saxagliptin/dapagliflozin under Qtern in certain markets. These products use more complex formulation and regulatory strategies than single-agent Onglyza.

Product	Active ingredients	Formulation challenge	Commercial opportunity
Onglyza	Saxagliptin	Low-dose immediate-release tablet	Standard generic competition
Kombiglyze XR	Saxagliptin plus metformin extended release	Bilayer or controlled-release architecture, depending on product design	Higher formulation and manufacturing barrier
Qtern	Saxagliptin plus dapagliflozin	Combination tablet with two diabetes mechanisms	Combination-product and adherence positioning
Saxagliptin/metformin immediate release	Saxagliptin plus metformin	Dose uniformity and high metformin loading	Potentially lower-cost generic alternative

Combination products create opportunities for excipient suppliers offering:

• Modified-release polymers
• Layered-tablet technologies
• High-load metformin excipient systems
• Taste-masking systems
• Robust coating platforms
• Integrated analytical and scale-up support

The commercial barrier is higher because each active ingredient may have separate bioequivalence, patent, labeling, and manufacturing considerations.

What patents protect Onglyza and its formulations?

Onglyza is protected primarily through patents covering saxagliptin, pharmaceutical compositions, methods of treatment, and combination products. The FDA Orange Book is the principal source for patents listed against approved U.S. products (FDA, n.d.-a).

The relevant patent categories are:

1. Composition-of-matter patents for saxagliptin and related chemical compounds.
2. Salt, crystal-form, or solid-state patents, where applicable.
3. Pharmaceutical composition patents.
4. Method-of-use patents for treating type 2 diabetes.
5. Combination-product patents covering saxagliptin with metformin or dapagliflozin.
6. Formulation patents directed to extended release or multi-active dosage forms.

The conventional excipients in the Onglyza immediate-release tablet are unlikely to create a meaningful standalone exclusivity barrier. A generic applicant would normally avoid the branded formulation's intellectual-property claims by using non-infringing excipient grades, different proportions, or an alternative manufacturing process, subject to bioequivalence and other ANDA requirements.

Patent expiry dates must be assessed against the current Orange Book listing, applicable pediatric extensions, terminal disclaimers, and any litigation settlements. Composition patents and combination-product patents can have materially different expiry dates. A single "Onglyza patent expiration date" is therefore not sufficient for launch planning.

When does Onglyza lose exclusivity and what generic entry risks exist?

Onglyza is a small molecule, so the relevant competitive pathway is an ANDA generic, not a biosimilar application. The risk profile is determined by:

• Listed Orange Book patents
• Regulatory exclusivity
• Paragraph IV certifications
• ANDA filing dates
• First-filer status
• Patent litigation
• Settlement terms
• Commercial launch decisions

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. If the patent holder files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments (FDA, n.d.-b).

Biosimilar risk

Biosimilar risk is not applicable to Onglyza because saxagliptin is a chemically synthesized small molecule. Competitive risk comes from generic saxagliptin tablets and authorized or third-party combination products.

Generic launch scenarios

Scenario	Market effect	Excipient opportunity
Single generic entrant	Moderate price erosion	Preferred supplier contracts and technical support
Several ANDA entrants	Rapid price compression	Low-cost, high-volume excipient supply
Authorized generic or branded-generic strategy	Greater price pressure	Contract manufacturing and dual-source supply
Combination-product entry	Slower, more complex competition	Modified-release and multilayer technologies
Delayed launch after patent settlement	Extended branded pricing	Continued supply to branded manufacturer

What is the FDA and Orange Book status of Onglyza?

Onglyza remains an FDA-approved saxagliptin product, with labeling covering 2.5 mg and 5 mg tablets. The FDA Orange Book identifies approved products and listed patents where applicable. The reference-listed product status, patent listings, exclusivity entries, and approved generic applicants should be checked in the current Orange Book and FDA Drugs@FDA records before making a launch or licensing decision (FDA, n.d.-a; FDA, n.d.-c).

For excipient companies, the most relevant regulatory documents are:

• The approved prescribing information
• FDA inactive ingredient databases
• Product-specific bioequivalence requirements
• Drug Master Files for excipient or coating systems
• Current good manufacturing practice records
• Stability and extractables data for packaging components

An excipient substitution is not automatically interchangeable from a regulatory perspective. The applicant must show that the finished product remains pharmaceutically equivalent and bioequivalent, and that the change does not alter safety, quality, or performance.

How strong is the Onglyza formulation patent estate?

The immediate-release tablet formulation has a moderate technical barrier but a limited apparent excipient barrier. The formulation uses widely available compendial excipients and does not depend on an unusual delivery system.

Patent strength is more likely to reside in:

• Saxagliptin chemistry
• Specific solid forms or salts
• Combination products
• Extended-release technologies
• Narrow method-of-use claims

The practical freedom-to-operate risk for a generic manufacturer is therefore more likely to arise from API, combination, or method-of-use patents than from lactose, cellulose, croscarmellose sodium, magnesium stearate, or standard film-coating components.

Which companies can capture commercial value from Onglyza excipients?

The strongest commercial positions are available to companies that combine excipient supply with formulation and regulatory services.

Excipient manufacturers

Suppliers can target:

• Direct-compression lactose
• High-functionality microcrystalline cellulose
• Croscarmellose sodium
• Low-peroxide or low-moisture excipients
• Film-coating premixes
• Iron oxide color systems
• Lubricants optimized for continuous manufacturing

Contract development and manufacturing organizations

CDMOs can offer generic sponsors:

• QbD formulation development
• Design-of-experiments studies
• Dissolution matching
• Scale-up support
• Stability programs
• ANDA-ready CMC documentation
• Alternate-source qualification

Generic drug manufacturers

Generic manufacturers can compete through:

• Lactose-free formulations
• Smaller tablets
• Lower-cost packaging
• Dual-source excipient strategies
• Combination products
• Regional manufacturing
• Hospital and government tenders

Revenue exposure for AstraZeneca is difficult to isolate because Onglyza sales may be reported within broader diabetes or alliance categories rather than as a separately disclosed product line. The product's mature lifecycle and competition from other DPP-4 inhibitors, GLP-1 products, SGLT2 inhibitors, and metformin-based therapies limit the likely premium for a differentiated excipient formulation (AstraZeneca, 2023).

What is the best excipient strategy for an Onglyza generic?

The preferred strategy is a conventional, low-risk formulation with controlled excipient variability rather than a heavily patented redesign.

A commercially defensible development plan would prioritize:

1. A reference-matched immediate-release tablet.
2. A lactose-free backup formulation.
3. High-functionality direct-compression excipients.
4. Two qualified sources for each critical excipient.
5. Dissolution robustness across manufacturing scales.
6. Packaging suitable for humid markets.
7. A separate development track for saxagliptin/metformin or other combination products.
8. A freedom-to-operate review focused on API, solid-state, combination, and method-of-use patents.

The largest near-term opportunity is likely to be dependable, low-cost supply for generic saxagliptin and combination products. The highest-margin opportunity is formulation and regulatory support for more complex combination or modified-release products.

Key Takeaways

• Onglyza is an immediate-release saxagliptin tablet with a conventional excipient system.
• The main excipients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and standard film-coating materials.
• The excipient system presents limited standalone patent protection.
• Generic competition, not biosimilar competition, is the principal lifecycle risk.
• Lactose-free, moisture-robust, smaller-tablet, and combination-product designs are the main formulation opportunities.
• The strongest IP risks are likely to involve saxagliptin chemistry, solid forms, combination products, and methods of use.
• Excipient suppliers can create value through high-functionality grades, dual sourcing, and CMC support rather than through a proprietary excipient claim alone.
• Current Orange Book listings, Paragraph IV certifications, litigation, and settlement terms must govern any launch assessment.

FAQs

Does Onglyza contain lactose?

Yes. The Onglyza tablet formulation includes lactose monohydrate as an inactive ingredient.

Can a generic saxagliptin product be lactose-free?

Yes. A generic applicant can develop a lactose-free formulation using another suitable diluent, provided the product satisfies applicable pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.

Is Onglyza an extended-release product?

Onglyza is an immediate-release saxagliptin tablet. Saxagliptin is also used in combination products with extended-release metformin, which creates a more complex formulation and patent landscape.

Are Onglyza excipients patented?

The conventional excipients themselves are widely used and generally do not create a strong standalone exclusivity barrier. Relevant intellectual-property risk is more likely to involve saxagliptin, solid forms, combinations, manufacturing methods, or therapeutic uses.

What is the best commercial opportunity for an Onglyza excipient supplier?

The strongest opportunity is supplying robust direct-compression and film-coating systems to generic manufacturers, supported by low-moisture grades, alternate-source qualification, dissolution data, and regulatory documentation.

References

1. AstraZeneca. (2023). Annual report and Form 20-F 2023. AstraZeneca PLC.

2. U.S. Food and Drug Administration. (2023). Onglyza (saxagliptin) prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.-b). Abbreviated new drug application approvals and patent certifications. FDA.

5. U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs database. FDA.